Never Again? Why the Avastin Hearing May Be One of a Kind
This article was originally published in RPM Report
Executive Summary
The two-day “streamlined withdrawal” hearing for Genentech’s breast cancer indication for Avastin was an unprecedented regulatory event. Based on how badly it went for the sponsor—and how uncomfortable it was for FDA—there may not be too many imitators any time soon.